CSPC Pharma stock falls 1.15 percent ahead of ESMO data

Published on 10/07/2026 at 05:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSPC Pharma stock traded at HKD 9.88 on October 7, 2026, before 8 oncology updates at ESMO. First-half revenue rose 40.1 percent to RMB 18,594 million.

CSPC Pharma, HK1093012172, Illustration mit AI erstellt.

CSPC Pharma stock (ISIN HK1093012172) was trading at HKD 9.88 on HKEX at 10:55 a.m. HKT on October 7, 2026, down 1.15 percent from HKD 10.00. The company is preparing an oncology pipeline presentation that could give the market a clearer view of its next growth phase.

Eight trials reach ESMO

According to CSPC Pharmaceutical Group on October 5, 2026, the group will present updates from 8 clinical trials at the European Society for Medical Oncology Congress in Madrid from October 23 to October 27, 2026. The program covers breast, lung, gastric, liver, colorectal and pancreatic cancers, as well as perivascular epithelioid cell tumors.

Fineline Cube reported on October 6, 2026, that 2 of the 8 studies were selected as late-breaking abstracts. One covers interim Phase III results for anbenitamab with HB1801 in first-line HER2-positive advanced breast cancer, while another covers updated overall survival in advanced gastric or gastroesophageal junction cancer.

Profit growth sets the baseline

CSPC Pharmaceutical Group reported first-half 2026 revenue of RMB 18,594 million, up 40.1 percent year over year. Reported profit attributable to shareholders reached RMB 6,094 million, an increase of 139.2 percent, while underlying profit rose 165.8 percent to RMB 6,164 million.

The earnings mix also shifted toward finished pharmaceuticals. That business generated RMB 16,100 million in first-half revenue, up 56.7 percent, while licensing income reached RMB 5,900 million, up 448.5 percent, according to the company's interim-results page. Gross margin increased 10.6 percentage points to 76.2 percent, and basic earnings per share rose 139.8 percent to RMB 53.45 cents.

Analysts see further upside

According to MarketScreener on September 14, 2026, the consensus rating was Buy across 24 analysts, with an average target of HKD 12.54. Against the HKD 9.88 trading price, that target lies 26.9 percent above the price.

The valuation case therefore depends on whether the ESMO presentations convert pipeline breadth into measurable clinical progress. The October event brings 8 trial updates and 2 late-breaking abstracts, while the latest financial report already shows revenue growth, accelerating profit and a higher gross margin.

CSPC Pharma stock trades below yearly high

CSPC Pharma stock was trading at HKD 9.88 on HKEX on October 7, 2026, with a market capitalization of HKD 112.7 billion and a 52-week range of HKD 6.53 to HKD 10.96.